IDNG - RedHawk Holdings Corp.
RedHawk Holdings Corp. , formerly Independence Energy Corp., is a diversified holding company which, through its subsidiaries, is engaged in sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. Through its medical products business unit, the Company sells WoundClot Surgical - Advanced Bleeding Control, the SANDD™ Insulin Needle Destruction Unit (formerly known as the Disintegrator™), the Carotid Artery Digital Non-Contact Thermometer and Zonis®. Through our United Kingdom based subsidiary, we manufacture and market branded generic pharmaceuticals, certain other generic pharmaceuticals known as “specials†and certain pharmaceuticals outside of the United Kingdom’s National Health Service drug tariff referred to as NP8’s. Its real estate leasing revenues are generated from various commercial properties under long-term lease. Additionally, RedHawk's real estate investment unit holds limited liability company interest in various commercial restoration projects in Hawaii. The Company's financial service revenue is from brokerage services earned in connection with debt placement services. RedHawk Energy holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System, a unique, closed cabinet, nominal dose transmission full body x-ray scanner.
Company website: http://www.redhawkholdingscorp.com/
Share Structure
Market Value1 $3,718,805 a/o Sep 06, 2017
Authorized Shares 450,000,000 a/o Jul 31, 2017
Outstanding Shares 361,049,027 a/o Jul 31, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 181,225,775 a/o Jun 07, 2017
Par Value No Par Value
ZERO DILUTION company is being funded by CEO and board members
New management have taken this company in a different direction and the results are evident from the recent Q. They a re laser focused on improving the company value and growing revenue.
Liabilities have been cut in half
Quaterly revenue has gone from 2016 - $9,750 >>> 2017 - $338,931
9 months revenue has gone from 2016 - $19,700 >>> 2017 - $1,556,548
Company went from a netloss in $672,026 2016 to net income of $169,353 in 2017 . Company is headed in the right direction by adding value and growing revenue while minimizing debt through acquisitions.
http://www.otcmarkets.com/edgar/GetFilingHtml...D=12128436
Company is under new management and is now run by G. Darcy Klug who is the Chairman and CFO and also owner of Beechwood Properties, LLC. Company is also in the process of having ticker symbol changed and is also suing former CEO for damageson-behalf of IDNG shareholders. Once this case settles/ or ruled in IDNG favor it will be a major boom to shareholders in recouping value. See below
RedHawk Sues Former Executive
The Lawsuit alleges the Defendants acquired 57,064,608 shares of Company’s common stock through securities fraud under Sections 10B and 20 of the Exchange Act and Rule 10b-5, securities fraud under Sections 18 and 20 of the Exchange Act, fraud under Louisiana state law. Beechwood is suing the Defendants for damages resulting from their breach of contract, unjust enrichment and for Schreiber’s breach of his fiduciary duties to the shareholders of RedHawk. The Lawsuit seeks damages from the Defendants, among other things, the return to the Company of all of the shares of RedHawk Holdings Corp. owned or acquired, now or previously, directly or indirectly, by the Defendants, along with any proceeds from any sales thereof. If successful, the return of the shares to RedHawk would inure to the benefit of all of the shareholders.
http://www.otcmarkets.com/stock/IDNG/news/Red...40&b=y
Recent News:
RedHawk Increases Ownership in EcoGen
RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today that RedHawk Pharma UK Ltd, a wholly-owned subsidiary of RedHawk, has completed the previously announced share transfer agreement to increase its ownership position in EcoGen Europe Ltd. (“EcoGen”) to 75%. Further ownership increases are possible as the Company continues to restructure and consolidate EcoGen’s operations, improve its profit margins and expand its stable of branded generic drugs offered in various European markets.
http://www.otcmarkets.com/stock/IDNG/news/Red...26&b=y
RedHawk Reports Third Quarter Earnings
RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today consolidated net income of $151,641 ($nil per share) on net revenues of $427,276 for the three month period ended March 31, 2017. On minimal revenues , RedHawk previously reported a net loss of $653,811 ($nil per share) for the comparable three month period ended March 31, 2016.
http://www.otcmarkets.com/stock/IDNG/news/Red...35&b=y
RedHawk Announces Second Quarter Results
RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today a consolidated net loss of $282,027 ($nil per share) on gross revenues of $718,337 for the three month period ended December 31, 2016. Excluding a non-recurring gain of $156,697, the Company reported a net loss of $291,810 ($nil per share) on minimal revenues for the comparable three month period ended December 31, 2015.
http://www.otcmarkets.com/stock/IDNG/news/Red...28&b=y
RedHawk Commences Sale of Branded Generics to Clinical Commissioning Groups
RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today that EcoGen Europe Limited (“EcoGen”) has commenced the process of selling its branded generic pharmaceutical drugs to a Clinical Commissioning Group (“CCG”). Initial deliveries of EcoGen’s branded generics to this first CCG are expected to commence during March 2017. There are currently 212 CCG’s and the Company believes more CCG’s will begin taking delivery of EcoGen’s branded generics in the coming months.
http://www.otcmarkets.com/stock/IDNG/news/Red...96&b=y
RedHawk to Expand Innovation Center Offices
RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today it is expanding its medical device warehousing and administrative offices at the Louisiana State University (“LSU”) Innovation Park (the “LSU Innovation Park”), a 200 plus acre university research park located five miles south of the main LSU campus in Baton Rouge, Louisiana. The Company said it hopes to complete the expansion of its innovation center offices by March 31, 2017 to address expected increased domestic and international demand for its medical devices.
http://www.otcmarkets.com/stock/IDNG/news/Red...86&b=y
RedHawk Holdings Corp. , formerly Independence Energy Corp., is a diversified holding company which, through its subsidiaries, is engaged in sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. Through its medical products business unit, the Company sells WoundClot Surgical - Advanced Bleeding Control, the SANDD™ Insulin Needle Destruction Unit (formerly known as the Disintegrator™), the Carotid Artery Digital Non-Contact Thermometer and Zonis®. Through our United Kingdom based subsidiary, we manufacture and market branded generic pharmaceuticals, certain other generic pharmaceuticals known as “specials†and certain pharmaceuticals outside of the United Kingdom’s National Health Service drug tariff referred to as NP8’s. Its real estate leasing revenues are generated from various commercial properties under long-term lease. Additionally, RedHawk's real estate investment unit holds limited liability company interest in various commercial restoration projects in Hawaii. The Company's financial service revenue is from brokerage services earned in connection with debt placement services. RedHawk Energy holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System, a unique, closed cabinet, nominal dose transmission full body x-ray scanner.
Company website: http://www.redhawkholdingscorp.com/
Share Structure
Market Value1 $3,718,805 a/o Sep 06, 2017
Authorized Shares 450,000,000 a/o Jul 31, 2017
Outstanding Shares 361,049,027 a/o Jul 31, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 181,225,775 a/o Jun 07, 2017
Par Value No Par Value
ZERO DILUTION company is being funded by CEO and board members
New management have taken this company in a different direction and the results are evident from the recent Q. They a re laser focused on improving the company value and growing revenue.
Liabilities have been cut in half
Quaterly revenue has gone from 2016 - $9,750 >>> 2017 - $338,931
9 months revenue has gone from 2016 - $19,700 >>> 2017 - $1,556,548
Company went from a netloss in $672,026 2016 to net income of $169,353 in 2017 . Company is headed in the right direction by adding value and growing revenue while minimizing debt through acquisitions.
http://www.otcmarkets.com/edgar/GetFilingHtml...D=12128436
Company is under new management and is now run by G. Darcy Klug who is the Chairman and CFO and also owner of Beechwood Properties, LLC. Company is also in the process of having ticker symbol changed and is also suing former CEO for damageson-behalf of IDNG shareholders. Once this case settles/ or ruled in IDNG favor it will be a major boom to shareholders in recouping value. See below
RedHawk Sues Former Executive
The Lawsuit alleges the Defendants acquired 57,064,608 shares of Company’s common stock through securities fraud under Sections 10B and 20 of the Exchange Act and Rule 10b-5, securities fraud under Sections 18 and 20 of the Exchange Act, fraud under Louisiana state law. Beechwood is suing the Defendants for damages resulting from their breach of contract, unjust enrichment and for Schreiber’s breach of his fiduciary duties to the shareholders of RedHawk. The Lawsuit seeks damages from the Defendants, among other things, the return to the Company of all of the shares of RedHawk Holdings Corp. owned or acquired, now or previously, directly or indirectly, by the Defendants, along with any proceeds from any sales thereof. If successful, the return of the shares to RedHawk would inure to the benefit of all of the shareholders.
http://www.otcmarkets.com/stock/IDNG/news/Red...40&b=y
Recent News:
RedHawk Increases Ownership in EcoGen
RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today that RedHawk Pharma UK Ltd, a wholly-owned subsidiary of RedHawk, has completed the previously announced share transfer agreement to increase its ownership position in EcoGen Europe Ltd. (“EcoGen”) to 75%. Further ownership increases are possible as the Company continues to restructure and consolidate EcoGen’s operations, improve its profit margins and expand its stable of branded generic drugs offered in various European markets.
http://www.otcmarkets.com/stock/IDNG/news/Red...26&b=y
RedHawk Reports Third Quarter Earnings
RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today consolidated net income of $151,641 ($nil per share) on net revenues of $427,276 for the three month period ended March 31, 2017. On minimal revenues , RedHawk previously reported a net loss of $653,811 ($nil per share) for the comparable three month period ended March 31, 2016.
http://www.otcmarkets.com/stock/IDNG/news/Red...35&b=y
RedHawk Announces Second Quarter Results
RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today a consolidated net loss of $282,027 ($nil per share) on gross revenues of $718,337 for the three month period ended December 31, 2016. Excluding a non-recurring gain of $156,697, the Company reported a net loss of $291,810 ($nil per share) on minimal revenues for the comparable three month period ended December 31, 2015.
http://www.otcmarkets.com/stock/IDNG/news/Red...28&b=y
RedHawk Commences Sale of Branded Generics to Clinical Commissioning Groups
RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today that EcoGen Europe Limited (“EcoGen”) has commenced the process of selling its branded generic pharmaceutical drugs to a Clinical Commissioning Group (“CCG”). Initial deliveries of EcoGen’s branded generics to this first CCG are expected to commence during March 2017. There are currently 212 CCG’s and the Company believes more CCG’s will begin taking delivery of EcoGen’s branded generics in the coming months.
http://www.otcmarkets.com/stock/IDNG/news/Red...96&b=y
RedHawk to Expand Innovation Center Offices
RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today it is expanding its medical device warehousing and administrative offices at the Louisiana State University (“LSU”) Innovation Park (the “LSU Innovation Park”), a 200 plus acre university research park located five miles south of the main LSU campus in Baton Rouge, Louisiana. The Company said it hopes to complete the expansion of its innovation center offices by March 31, 2017 to address expected increased domestic and international demand for its medical devices.
http://www.otcmarkets.com/stock/IDNG/news/Red...86&b=y
